搜尋結果
Merck KGaA shares plunge after cancer drug hopeful fails
Reuters· 1 日前, opens new tab slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head ...
Clinical Trial Of Ketamine Tablets Shows Promising Results For Treatment-Resistant Depression
Forbes· 1 日前A phase 2 clinical trial of 231 patients with treatment-resistant depression found that the ...
Japanese Beauty Is Suddenly Expanding In The U.S.—Why Just Now?
Forbes· 1 日前Japanese beauty (J-beauty) is finally expanding its reach in the U.S. The breakthrough is a ...
Dynatrace Stock Down 17% But Generative AI Could Boost Its Shares
Forbes· 1 日前While many companies are talking about generative AI, very few — notably Nvidia, Supermicro, ...
Council Post: The Future Of Neurotechnology: Five Trends To Watch
Forbes· 1 日前Neurotechnology, the fusion of neuroscience and technology, is revolutionizing the way we ...
Council Post: Why Digital Marketing Teams Should Apply The Mixture Of Experts AI Approach
Forbes· 1 日前Joe Rowett is the CEO of VELOX Media, a 5X Inc. 5000 company. Effective digital marketing is ...
Council Post: 4 Lessons Charitable Nonprofits Can Learn From The For-Profit Space
Forbes· 2 日前Charitable nonprofit organizations with a 501(c)(3) status are distinct in the United States ...
A Psychologist Reveals The Unexpected Benefits Of Swearing
Forbes· 2 日前A review paper published this month in Frontiers In Psychology unearthed the various reasons why swearing, often considered ...
5 Startup Opportunities In Anti-Ageing
Forbes· 2 日前As more and more people around the world have access to better nutrition and healthcare, the ...
Wegovy, Ozempic Are Overpriced By 400-500%: Here’s A Speedy Solution
Forbes· 2 日前A whopping 1 in 8 U.S. adults have taken GLP-1 drugs like Wegovy and Ozempic for weight loss ...